高级检索
当前位置: 首页 > 详情页

Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.

文献详情

资源类型:
Pubmed体系:
机构: [1]Lymphoma Research Laboratory, Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Hong Kong [2]Cancer Epigenetics Laboratory, Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong [3]Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong [4]Department of Pathology, West-China Hospital of Sichuan University, Chengdu, Sichuan, China [5]Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan [6]Division of Hematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
出处:
ISSN:

摘要:
Nasal-type natural killer/T-cell lymphoma (NKTCL) is an aggressive disease characterized by frequent deletions on 6q, and constitutive activation of signal transducer and activator of transcription 3 (STAT3). Phosphorylation at Tyr705 activates STAT3, inducing dimerization, nuclear translocation, and DNA binding. In this study, we investigated whether receptor-type tyrosine-protein phosphatase κ (PTPRK), the only protein tyrosine phosphatase at 6q that contains a STAT3-specifying motif, negatively regulates STAT3 activation in NKTCL. PTPRK was highly expressed in normal NK cells but was underexpressed in 4 of 5 (80%) NKTCL cell lines and 15 of 27 (55.6%) primary tumors. Significantly, PTPRK protein expression was inversely correlated with nuclear phospho-STAT3(Tyr705) expression in NKTCL cell lines (P = .025) and tumors (P = .040). PTPRK restoration decreased nuclear phospho-STAT3(Tyr705) levels, whereas knockdown of PTPRK increased such levels in NKTCL cells. Phosphatase substrate-trapping mutant assays demonstrated the binding of PTPRK to STAT3, and phosphatase assays showed that PTPRK directly dephosphorylated phospho-STAT3(Tyr705). Restoration of PTPRK inhibited tumor cell growth and reduced the migration and invasion ability of NKTCL cells. Monoallelic deletion and promoter hypermethylation caused underexpression of PTPRK messenger RNA in NKTCL, and methylation of the PTPRK promoter significantly correlated with inferior overall survival (P = .049) in NKTCL patients treated with the steroid-dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide regimen. Altogether, our findings show that PTPRK underexpression leads to STAT3 activation and contributes to NKTCL pathogenesis. © 2015 by The American Society of Hematology.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 1 区 医学
小类 | 1 区 血液学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 血液学
第一作者:
第一作者机构: [1]Lymphoma Research Laboratory, Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Hong Kong
共同第一作者:
通讯作者:
通讯机构: [1]Lymphoma Research Laboratory, Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Hong Kong [*1]Department of Pathology, The University of Hong Kong, Queen Mary Hospital Compound, 102 Pokfulam Rd, Hong Kong
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号